초록 ▼

A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhala

A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.

대표청구항 ▼

[ What is claimed is:] [1.] A process for the manufacture of a pharmaceutical composition suitable for administration by oral inhalation from a dry powder inhaler device, comprisingproviding a solution in which are dissolved (a) a pharmaceutically active polypeptide, and (b) an enhancer compound whi

[ What is claimed is:] [1.] A process for the manufacture of a pharmaceutical composition suitable for administration by oral inhalation from a dry powder inhaler device, comprisingproviding a solution in which are dissolved (a) a pharmaceutically active polypeptide, and (b) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient;removing the solvent from said solution to yield a dry solid comprising said polypeptide and said enhancer compound;pulverizing said dry solid to produce a powder, wherein at least 50% of the total mass of said powder is in the form of primary particles having a diameter less than about 10 microns, said primary particles being optionally agglomerated; andloading the powder into a dry powder inhaler device adapted for inhalation through the mouth.